Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• The COVID-19 pandemic caused over 200 million infections and 4 million deaths globally.
• Novel COVID-19 vaccines are available, but their safety and efficacy are still debated.
• Alternative SARS-CoV-2 prevention strategies have been largely overlooked.

Purpose of the Study:

• To re-evaluate hydroxychloroquine (HCQ) as a potential pre-exposure prophylaxis (PrEP) for SARS-CoV-2 infection.
• To address the dismissal of HCQ due to flawed studies and political controversy.
• To highlight HCQ's potential value in preventing SARS-CoV-2.

Main Methods:

• Review of existing studies on hydroxychloroquine for SARS-CoV-2.
• Analysis of data potentially obscured by flawed research and political discourse.
• Examination of HCQ's role in pre-exposure prophylaxis.

Main Results:

• Existing studies on HCQ efficacy may be compromised by methodological flaws.
• Political controversy has unfairly dismissed hydroxychloroquine as a viable treatment option.
• Evidence suggests hydroxychloroquine could serve as a valuable pre-exposure prophylaxis.

Conclusions:

• Hydroxychloroquine (HCQ) warrants further investigation as a pre-exposure prophylaxis (PrEP) for SARS-CoV-2.
• The potential benefits of HCQ have been underestimated due to flawed research and controversy.
• Alternative prevention methods like HCQ should be considered alongside vaccination strategies.